Investor’s Watch List: Ultrapar Participacoes S.A. (NYSE:UGP), Heron Therapeutics, Inc. (NASDAQ:HRTX)

6

Ultrapar Participacoes S.A. (NYSE:UGP)

Ultrapar Participacoes S.A., a major Brazilian industrial group, is one of the largest distributors of liquefied petroleum gas in Brazil and a leading producer of petrochemicals and chemical. Ultrapar is also engaged in the storage and transportation of liquefied petroleum gas and petrochemical and chemical products. (PRESS RELEASE)

Ultrapar Participacoes S.A. (NYSE:UGP)’s Financial Overview

Ultrapar Participacoes S.A. (NYSE) surged 3.39% yesterday to close its trading session at $12.51. The company has 1 year Price Target of $17.2. Ultrapar Participacoes S.A. has 52-Week high of $26.48 and 52-Week Low of $8.86. The stock touched its 52-Week High on 26.48 and 52-Week Low on 8.86. The stock traded with the volume of 1.16 Million shares yesterday. The firm shows the market capitalization of $7.13 Billion.

Ultrapar Participacoes S.A. (NYSE) reported its last quarterly earnings on 3/30/2018 where the firm reported its Actual EPS of $0.04/share against the analyst consensus estimate of $0.07/share. The difference between the actual and expected EPS is $-0.03 a share with a surprise factor of -42.9%.

The firm is trading with SMA20 of 8.7 Percent, SMA50 of 13.28 Percent and SMA200 of -9.97 percent. Ultrapar Participacoes S.A. has P/S value of 0.31 while its P/B value stands at 2.84. Similarly, the company has Return on Assets of 3.6 percent, Return on Equity of 11.4 percent and Return on Investment of 9 Percent. The company shows Gross Margin and Operating Margin of 7.4 percent and 2.2 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 2.8 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 11 analysts offering 12-month price forecasts for Ultrapar Participacoes SA have a median target of 13.23, with a high estimate of 17.07 and a low estimate of 10.40. The median estimate represents a +5.77% increase from the last price of 12.51.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Heron Therapeutics, Inc. (NASDAQ:HRTX)

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.

Heron Therapeutics, Inc. (NASDAQ:HRTX)’s Financial Outlook

The 11 analysts offering 12-month price forecasts for Heron Therapeutics Inc have a median target of 54.00, with a high estimate of 76.00 and a low estimate of 42.00. The median estimate represents a +93.69% increase from the last price of 27.88.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Heron Therapeutics, Inc. has a Consensus Recommendation of 1.1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 0% and closed its last trading session at $27.88. The company has the market capitalization of $2.12 Billion. The stock has 52-week high of $42.9 and 52-Week low of $15. The firm touched its 52-Week high on 42.90 and 52-Week low on 15.00. The company has volume of 925177 shares. The company has a total of 76.17 Million shares outstanding.

Heron Therapeutics, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.49/share where the analyst estimated EPS was $-0.45/share. The difference between the actual and Estimated EPS is $-0.04. This shows a surprise factor of -8.9 percent.

The company has YTD performance of 54.03 percent. Beta for Heron Therapeutics, Inc. stands at 1.46 while its ATR (average true range) is 1.67. The company has Weekly Volatility of 4.35%% and Monthly Volatility of 6.05%%.

Heron Therapeutics, Inc. has distance from 20-day Simple Moving Average (SMA20) of 1.78%, Distance from 50-Day Simple Moving Average of -2.84 percent and Distance from 200-Day Simple Moving Average of -12.04%.

The Company currently has ROA (Return on Assets) of -54.8 percent, Return on Equity (ROE) of -72.2 Percent and Return on Investment (ROI) of -121.8% with Gross margin of 70.6 percent and Operating & Profit margin of 0% and 0% respectively.

SHARE